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Malaria: an update on treatment of adults in non-endemic
countries
Christopher J M Whitty, David Lalloo, Andrew Ustianowski
Every year people die from malaria in Britain and other industrialised countries. Most of these
deaths are avoidable: they occur because a patient or doctor has underestimated the severity of the
disease or has not considered the diagnosis early enough. This article provides the essential facts on
treating malaria in adults in a non-endemic setting and is based on the best available evidence
Treating uncomplicated falciparum
malaria
The key is to give an effective antimalarial at an
appropriate dose and ensure that patients complete the
course. Several oral drugs have good activity against
falciparummalaria, but drug resistance means that drug
combinations are always preferable. Most trials of anti-
malarials have been conducted in endemic countries
where there is at least some immunity to malaria, and
this means they may overestimate the efficacy of these
drugs in non-immune patients (because patients with
immunity tend to clear parasites more readily). There
are a few systematic reviews of antimalarials, but most
are for drugs that are not appropriate for use inWestern
countries in non-immune people (such as amodia-
quine). Systematic reviews, and in particular meta-
analyses, are of limited use for assessing the efficacy of
drugs such as antimalarials, for which resistance patterns
vary widely both in place and time.
The Health Protection Agency Advisory Commit-
tee on Malaria Prevention for UK Travellers has
reviewed the recent data and considers that the best
options for treating uncomplicated malaria are:
x Quinine, either for five days or until the parasites
have been cleared from the blood, followed by
x Doxycycline for seven days or
x Clindamycin for seven days or
x Sulfadoxine-pyrimethamine (Fansidar)
x Artemether-lumefantrine for three days (six dose
regimen)
x Atovaquone-proguanil for three days.
x Clinical failures can occur with any of these combi-
nations, but failure rates are low if the course is
completed. The agency’s advice is frequently updated
and can be accessed at www.hpa.org.uk/infections/
topics_az/malaria/guidelines.htm
Special cases
In patients from South East Asia there is evidence of
partial quinine resistance, and the non-quinine combi-
nations may be preferable.
In pregnant women quinine is advised because its
side effect profile in pregnancy is known: it is generally
safe, although it increases the risk of hypoglycaemia
and may induce labour. Doxycycline is contraindicated
in pregnancy. There are insufficient data on
atovaquone-proguanil to advise its use in pregnancy.
There are concerns about using artemether in early
pregnancy, and it should be avoided in the first trimes-
ter unless there is a clear reason (such as drug
resistance) to recommend it until more data are
available.
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Summary points
Malaria is common: you should assume that
patients who are unwell on returning from
tropical areas, especially Africa, have malaria until
proved otherwise. They do not have to have a
fever, although most will have history of fever
The severity of falciparum malaria is easily
underestimated: patients can deteriorate rapidly
despite treatment. You should admit patients to
hospital for initial treatment. Patients with
non-falciparum malaria seldom need
admission
For patients with a mild or moderate attack of
falciparum malaria, consider oral quinine
(followed by a second drug),
atovaquone-proguanil, or
artemether-lumefantrine. The choice of drug may
depend on where they have visited; rates of drug
resistance vary from country to country
For a patient with severe or potentially
complicated disease, you should use parenteral
quinine or artesunate. You should give a loading
dose for quinine
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Quinine followed by a second drug
This is the standard treatment against which other
combinations are assessed in the UK. Resistance to
sulfadoxine-pyrimethamine monotherapy is now high
outside west Africa.
Side effects
Quinine—Nausea, mild deafness, and mild tinnitus (cin-
chonism) occur almost invariably in patients taking
quinine. These are reversible when the patient stops
taking the drug. Quinine can induce arrhythmias in
people with a pre-existing cardiac condition, although
this does not often happen at the doses used in oral
treatment.
Sulfadoxine-pyrimethamine—In common with other
sulphur containing drugs, this can cause skin rashes,
and rare cases of Stevens-Johnson syndrome have
been reported.
Doxycycline—This can cause gastritis, photo-
sensitivity, and all the problems associated with broad
spectrum antibiotics.
Clindamycin—Possible increased risk of colitis from
Clostridium difficile.
Evidence
Quinine became established as the standard treatment
for falciparum malaria before the development of
modern trial methods. No placebo controlled studies
were performed, and none would now be ethical. Many
studies have compared new treatments against
quinine, and its continuing effectiveness in Africa has
been repeatedly shown. There is reasonable evidence
quinine has become less effective in South East Asia.
Dose
Quinine—600 mg (in adults) three times a day for five
days, or until parasites have cleared from the
peripheral blood, followed by
Sulfadoxine-pyrimethamine three tablets once only or
Doxycycline 100 mg daily for seven days or
Clindamycin 450 mg every eight hours for seven
days.
Atovaquone-proguanil (Malarone)
This probably has a slightly higher failure rate than
quinine combinations, but it is reported to be slightly
better tolerated. Evidence for both these statements is
weak, with few properly powered comparisons with
other effective drug regimens in non-immune adults.
Currently, no part of the world has specific problems
with atovaquone-proguanil resistance. However, if
patients have been taking it as prophylaxis,
atovaquone-proguanil is not the best choice for
treatment because of the risk that the malaria parasite
will be resistant.
Side effects—Gastritis and nausea are relatively
common.
Evidence—One systematic review of eight trials
found it had equivalent efficacy to that of other
regimens for treating uncomplicated falciparum
malaria.1
Dose—Four tablets once daily for three days in
adults.
Artemether-lumefantrine (Coartemether, Coartem,
Riamet)
A four dose regimen for this drug has not been proved
to be effective, but a six dose regimen seems to be
effective against parasites from all parts of the world. It
should be taken with fatty foods to achieve maximum
drug concentrations.
Side effects—It is generally well tolerated.
Evidence—Systematic reviews suggest that, although
the original four dose regimen of artemether-
lumefantrine was not effective, the six dose regimen is
effective, and the latter regimen should always be used,
though evidence for its efficiacy in non-immune adults
is limited.2 No significant difference was seen between
six dose artemether-lumefantrine and artesunate-
mefloquine in a recent study from Laos.3
Dose—For adults, four tablets (each comprising 20
mg artemether and 120 mg lumefantrine) followed by
a further four tablets at eight hours and then twice
daily for two days.
Treating non-falciparum malaria
When a diagnosis of malaria caused by Plasmodium
vivax, P ovale, or P malariae is made, the key to success-
ful management is to be sure that the patient does not
have malaria caused by P falciparum or a mixed
infection. This mistake is easily made, especially in
laboratories that rarely see malaria. The following con-
ditions should raise questions about the diagnosis:
A very sick patient
A very high parasite count
A patient arriving from Africa (where over 90% of
malaria will be falciparum).
Non-falciparummalaria seldom leads to death, and
patients can almost always be treated as outpatients.
Almost all parasites are chloroquine sensitive, and
chloroquine remains the drug of choice to treat acute
infection. True vivax resistance to chloroquine has
been reported, especially in Indonesia, but it remains
extremely rare in travellers.
Vivax and ovale malaria lay down hypnozoites in
the liver, which can cause relapse after months or even
years. Hypnozoites are not reliably killed by chloro-
quine, or indeed any of the drugs used to treat acute
infection. Only one drug, primaquine, that has been
shown to work against hypnozoites (“radical cure”) is
licensed in Europe.
Chloroquine
This works rapidly and reliably where there is no resist-
ance, is safe in usual doses, and is well tolerated. It is
considered safe in pregnancy.
Side effects—It can cause gastritis and mild
abdominal pain. It can cause itching in some people of
African ethnicity (mechanism unknown).
Evidence—Chloroquine became established as the
standard treatment for non-falciparum malaria before
the development of modern trial methods. Case series
suggest it remains effective in almost all geographical
areas ( > 98% cure rates) and should remain the first
line treatment, although occasional failures do occur
with vivax malaria, especially in cases from eastern
Asia.
Dose—600 mg orally and then 300 mg at six hours,
24 hours, and 48 hours.
Primaquine
Used for radical cure of hypnozoites, primaquine
needs prolonged courses of treatment (14 days). It is
contraindicated in people with glucose-6-phosphate
Practice
242 BMJ VOLUME 333 29 JULY 2006 bmj.com
dehydrogenase deficiency, in whom it can cause severe
haemolysis, and it should not be prescribed until a test
for deficiency has been performed. Specialist advice
should be sought in those with glucose-6-phosphate
dehydrogenase deficiency. Primaquine is also contra-
indicated for pregnant women.
Evidence—There have been no systematic reviews,
and many of the case series predate 1977. Studies have
shown increased relapse rates with decreased doses or
with increasing primaquine resistance.4 There is
increasing evidence that treatment for fewer than 14
days is suboptimal and that 30 mg a day should now be
used.
Dose—15 mg twice daily (total of 30 mg a day) for 14
days.
Treating severe falciparum malaria
Early identification of severe or potentially compli-
cated malaria is important. Symptoms and signs that
should alert you to this are shown in the box.
In Western countries once patients present to acute
medical facilities, deaths occur because of cerebral
malaria, usually in the first 48 hours of hospitalisation,
or acute respiratory distress syndrome (which can
occur later, even after parasites have been cleared).
Renal failure can be managed by haemofiltration or
dialysis in hospital. Always check for hypoglycaemia if
patients are drowsy, unconscious, or fitting.
The key intervention, and the only one for which
there is strong evidence, is to give an effective anti-
malarial at an adequate dose parenterally. All other
decisions are secondary.
Antimalarial treatments
The current options are:
x Quinine (intravenous)
x Artesunate (intravenous)
x Artemether (intramuscular)—Probably less effective
than artesunate, although no studies have compared
them directly.
Compared with quinine, the artemisinins reduce
parasite counts faster, and there is now evidence from
Asia that they reduce mortality in adults with severe
malaria. There are no good studies comparing intra-
venous quinine with artesunate in Africa, where there
are different patterns of drug resistance. Quinine
remains a good drug to treat severe malaria. At
present, good quality intravenous artesunate is in short
supply in Europe and is available only in specialist cen-
tres. Preferences for a particular drug should never
delay treatment with one of them in adequate doses.
There are a few situations where artesunate should
be considered:
x Patients from South East Asia might have relatively
quinine resistant malaria, so an artemisinin is
preferable. Trial evidence supports such patients being
given artesunate
x Quinine is pro-arrhythmogenic, so artemisinins
should be considered in patients with a cardiac condi-
tion
x Artemisinins reduce parasites faster, so may be
preferable in patients with a parasite count > 10%, but
it is not clear what effect exchange transfusion has on
artemisinin blood concentrations, so use only one or
the other. There is more evidence to support the use of
artesunate than exchange transfusion.
Artemisinins should be used with caution in early
pregnancy unless there is a clear indication for them
(such as suspected quinine resistant disease from
South East Asia). There is insufficient evidence from
human studies, and animal studies suggest teratogenic-
ity is a possibility in the first trimester.
Side effects
The side effects of intravenous quinine are as for oral
quinine, with the addition of arrhythmias and hypogly-
caemia. Artemisinins are generally well tolerated.
Evidence
Quinine became established as the standard treatment
for severe malaria before the development of modern
trial methods. Randomised placebo controlled trials
have not been done and would now be unethical. A
systematic review of four randomised controlled trials
found that loading doses of quinine reduced parasite
and fever clearance times compared with standard
doses; there was a trend to reduce mortality which
failed to reach statistical significance.5 There was no
apparent effect on coma recovery time, neurological
sequelae, or seizures.5
Two systematic reviews have compared intramus-
cular artemether with quinine.6 7 One showed that
artemether produced faster parasite clearance but
made no difference in mortality, fever clearance, coma
recovery time, or neurological sequelae. The combined
outcome of death and neurological sequelae was
significantly lower for artemether, however. The other
review found a small decrease in mortality with
artemether (which lost significance when the poorer
quality randomised controlled trials were excluded)
but no difference in neurological sequelae.
Faster parasite clearance has been seen with
artesunate compared with quinine; there were no
differences in fever clearance time, coma recovery,
neurological sequelae, or mortality in one study,8 but a
Indicators of severe or potentially complicated
malaria in adults
Severe malaria
• Any neurological signs, drowsiness, or fitting.
Cerebral malaria is strictly defined as unrousable coma
in the presence of malaria, but any patient who is
drowsy or has neurological symptoms should be
treated the same way
• Oliguria, renal failure
• Respiratory distress due to pulmonary oedema or
acute respiratory distress syndrome
• Disseminated intravascular coagulation
• Severe anaemia.
• Shock
• High plasma lactate, hypoglycaemia
Potentially complicated malaria
• Parasite count > 2%
• Jaundice
• Pregnancy
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more recent, large, multicentre study from South East
Asia demonstrated a survival benefit for artesunate in
adults.9
Dose
Quinine 10 mg/kg (maximum 700 mg) given
intravenously twice daily (loading dose 20 mg/kg
(maximum 1400 mg))
Artesunate 2.4 mg/kg given intravenously at 0, 12,
and 24 hours, and then daily
Artemether 3.2 mg/kg given intramuscularly as
loading dose, then 1.6 mg/kg given intramuscularly
daily (to total of 640 mg).
Artesunate and artemether should be followed by
doxycycline (100 mg daily for seven days) or
artemether-lumefantrine, and quinine should be
followed by sulfadoxine-pyrimethamine, doxycycline,
or clindamycin (as for uncomplicated malaria).
Adjunctive treatments
Various adjunctive treatments have been tried. Few, if
any, work, and some are harmful. Among the
commonly considered treatments, corticosteroids and
mannitol have been shown not to work in cerebral
malaria.
Exchange transfusion remains controversial: evi-
dence from trials is contradictory, and it is unlikely that
further trials will settle this question. Nobody would
advise exchange transfusion for a parasitaemia < 10%.
At higher parasite counts the evidence is mixed; most
centres with expertise in malaria consider exchange
transfusion if parasite counts are > 20%, but some cen-
tres never use it. In practice, there is general agreement
that the effect is probably marginal.
Prophylactic anticonvulsants used to be given to
patients with cerebral malaria, but, although it reduced
the risk of fits, a trial of phenobarbital (in children)
suggested an excess mortality. Anticonvulsants should
now be reserved for patients who are actively fitting.
Haemofiltration will need to be considered in cases
of acute renal failure. Renal failure secondary to
malaria almost invariably resolves completely,
although this can take days and occasionally weeks.
Antibiotics—Patients whose blood pressure drops
may have coexisting sepsis caused by Gram negative
bacteria and should be considered for broad spectrum
antibiotics. Malaria seldom causes major haemo-
dynamic collapse directly.
Diuretics—Pulmonary oedema can be treated with
diuretics, but these may be ineffective in patients with
coexisting malaria induced renal failure. In these cases
haemofiltration will be needed.
Acute respiratory distress syndrome is the most
concerning complication of malaria in adults that
develops after the first 24 hours of acute illness. The
treatment is as for all other causes of acute respiratory
distress syndrome. There is weak evidence that heavy
hydration increases the risk of the syndrome develop-
ing; patients need to be adequately hydrated, but “run-
ning patients wet” is not advised by most centres with
expertise in malaria.
Evidence
Corticosteroids—One systematic review examined two
randomised controlled trials comparing dexametha-
sone with placebo in severe cerebral malaria.10 There
were no differences in mortality but increased
gastrointestinal bleeding and seizures in the dexa-
methasone groups.
Clinical tips
• Debates about adjunctive treatment, such as
exchange transfusion, should never delay giving an
effective antimalarial in sufficient doses to patients
with malaria. Effective antimalarial drugs are the only
interventions that definitely improve outcome
• People repeatedly exposed to malaria can become
semi-immune (so getting less severe attacks of
malaria), but it is not possible to make accurate
judgments of individuals’ immune status from their
ethnicity or country of residence. It is dangerous to
base decisions on such judgments. You should assume
that all patients presenting in non-endemic countries
(such as the UK) have no immunity
• You should seek up to date advice on the treatment
of
Patients with severe falciparum malaria travelling
from South East Asia (where there is multidrug
resistant malaria)
Pregnant women.
• Assume that all falciparum malaria is resistant to
chloroquine
• Vivax malaria that is resistant to chloroquine is still
rare. Chloroquine remains the drug of choice for
non-falciparum malaria. Primaquine is contraindicated
in patients with glucose-6-phosphate dehydrogenase
deficiency
• Patients treated with quinine are likely to get
transient nausea, deafness, and tinnitus, and they
should be warned about this
• Beware of hypoglycaemia in drowsy or comatose
patients, especially if they are pregnant
• The Advisory Committee on Malaria Prevention in
UK Travellers (ACMP) provides up to date guidance
on treatment and prevention of malaria. Advice on
managing complex cases can be obtained from the
Hospital for Tropical Diseases or the Liverpool School
of Tropical Medicine.
Sample questions
1. A pregnant woman presents with otherwise
uncomplicated malaria in her first trimester after a trip
to Kenya. Which is the best drug or combination to
use for treatment
a. Atovaquone-proguanil
b. Artemether-lumefantrine
c. Quinine
2. A patient you have started to treat for severe malaria
gradually becomes unconscious. Which of the
following would be appropriate management in
addition to antimalarials?
a. Checking for hypoglycaemia
b. Corticosteroids
c. Mannitol to reduce intracerebral pressure.
3. In a patient with vivax malaria
a. Chloroquine resistance is now common
b. Glucose-6-phosphate dehydrogenase deficiency
needs to be looked for before primaquine treatment
only if the patient is anaemic
c. In patients from Africa consider double checking
the diagnosis
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Mannitol—One systematic review failed to identify
any randomised or quasi-randomised controlled
trials.11 Mannitol has been shown to control intracra-
nial pressure in children with cerebral malaria, but
effects on morbidity or mortality are unclear.12
Exchange transfusions—There are no suitable ran-
domised controlled trials for analysis, but a systematic
review of case-control studies found variable efficacy
and no influence on mortality overall.13
Prophylactic anticonvulsants—One systematic review
of three randomised controlled trials comparing
phenobarbital with placebo (no treatment) found
fewer convulsions but increased mortality in the
phenobarbital group.14
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A bipolar story
Being a medical student has its ups and downs. As I sat
in the busy psychiatric outpatient clinic, I was having a
particularly “up” day, giggling while the senior house
officer vainly tried to hang up the telephone. On the
other end was a bipolar patient, currently manic. “Yes, I
understand, but I really have to go . . . Yes, goodbye . . .
No, I am in a clinic. . ..”
“Pressure of speech,” I ruminated, proud at how
good my psychiatric terminology was coming along on
only the second day of my attachment. When my
colleague finally managed to disentangle himself from
the conversation, he looked at me with a strangely
vindictive grin and told me that the patient was being
admitted and that she would be a “wonderful
candidate” for a detailed case study. My shoulders
sagged, my grin turned upside down—I’d been looking
forward to lunch and a free afternoon. Little did I
know what I was in for.
“Can I see your badge, young lady? It’s just I have to
make sure you’re not an actor pretending to be a
medical student. There are a lot of actors here, you
know—the patients, the doctors. . ..”
“No further explanations needed,” I thought, and
duly produced my identity badge. Immediately
convinced of the veracity of my identity, my patient sat
down in the family room of the inpatient ward, and I
proceeded to obtain a full, detailed psychiatric
history—or rather, I tried to. The truth is, she just
talked—about everything from art, to politics, to
literature. Because of my complete inability to direct
the interview, I let her carry on. “Been here almost
three hours already . . . Damn, shouldn’t have giggled at
the SHO. Never mind, I’ll just have to come back again
tomorrow.” Resigned to the fact that I’d have to meet
this patient many times before I could get all the
relevant facts, I relaxed and was surprised to find
myself enjoying all the irrelevant bits of the
conversation.
We both laughed and chuckled like a couple of
schoolgirls, me and this 65 year old woman, as I got
caught up in her contagious joy and boundless energy.
Amid deliberations on Monet and reflections on the
situation in the Middle East, she told me about her
experience of terrible confusion that somehow, like in
a dream, makes perfect sense. I heard about her tragic
losses and deep despair, about the havoc this disease
can wreck on a family and about how her faith had
sustained her throughout. “Mania . . . psychosis . . .
depression.” She didn’t just give me a history of bipolar
illness, she told me a story and took me on a journey
to discover a person struggling with a disease but who,
in spite of or perhaps because of it, was a whole and
wonderful human being.
Now, when I meet a “bipolar,” “depressed,” or
“schizophrenic” patient, I try to look past the diagnosis
and often find someone who has had to endure more
than most of us and thus has a wealth of experiences
and stories to share. While we may not always have the
luxury of time to listen, these are people who deserve
all our compassion and respect.
“You’re my angel,” my patient gushed as she gave me
a hug. She was wrong, of course, just “over-familiarity.”
The truth is, she was mine.
Raquel Duarte fourth year medical student, University of
Edinburgh, Edinburgh (s0126305@sma.ed.ac.uk)
We welcome articles up to 600 words on topics such as
A memorable patient, A paper that changed my practice,My
most unfortunate mistake,or any other piece conveying
instruction, pathos, or humour. Please submit the
article on http://submit.bmj.com Permission is needed
from the patient or a relative if an identifiable patient is
referred to. We also welcome contributions for
“Endpieces,” consisting of quotations of up to 80 words
(but most are considerably shorter) from any source,
ancient or modern, which have appealed to the reader.
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